Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer [Gastrointestinal Cancer]
Conclusion
Olaparib/paclitaxel is active in the treatment of patients with metastatic gastric cancer, with a greater OS benefit in ATMlow patients. A phase III trial in this setting is under way.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Bang, Im, Lee, Cho, Song, Lee, Kim, Park, Chun, Zang, Fielding, Rowbottom, Hodgson, O'Connor, Yin, Kim Tags: Combined Modality, Translational Oncology Gastrointestinal Cancer Source Type: research
More News: Ataxia | Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Oral Cancer | Study